sponsored
PatientsVille.com Logo

PatientsVille

Risperdal Medical Research Studies

Up-to-date List of Risperdal Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Risperdal Medical Research Studies

Rank Status Study
1 Unknown  High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone
Conditions: Schizophrenia;   Schizoaffective Disorder
Interventions: Drug: long-acting injectable risperidone;   Drug: long acting injectable risperidone
Outcome Measures: The primary end point will be change in PANSS Positive Subscale Score in the high dose group using a mixed model ANOVA;   change in PANSS; time to discontinuation for lack of efficacy and tolerability; change in cognitive domain scores; comparative incidence and time course of EPS, hyperprolactinemia, plasma lipids, weight gain, and other side effects between treatments
2 Unknown  Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning
Condition: Schizophrenia
Interventions: Drug: Risperidone;   Drug: Paliperidone
Outcome Measure: Comparison of BOLD signal activation and FDG metabolism of the DLPFC, superior temporal gyrus and amygdala, and their interaction between Invega and Risperdal
3 Recruiting Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
Conditions: Psychotic Disorders;   Schizophrenia;   Bipolar Disorder;   Depressive Disorder
Interventions: Drug: Aripiprazole, oral formulation;   Drug: Olanzapine, oral formulation;   Drug: Paliperidone, oral formulation;   Drug: Paliperidone, LAI;   Drug: Quetiapine, oral formulation;   Drug: Risperidone, oral formulation;   Drug: Risperidone, LAI
Outcome Measures: Aripiprazole concentration in venous and capillary plasma;   Paliperidone concentration in venous and capillary plasma;   Olanzapine concentration in venous and capillary plasma;   Quetiapine concentration in venous and capillary plasma;   Risperidone concentration in venous and capillary plasma;   Number of participants with an adverse event as a measure of safety
4 Recruiting A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis
Condition: Methamphetamine Dependence
Interventions: Drug: paliperidone;   Drug: Risperidone
Outcome Measures: The severity of psychosis;   Clinical general status
5 Recruiting Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia
Condition: Schizophrenia (Recent-onset)
Interventions: Drug: paliperidone palmitate;   Drug: risperidone
Outcome Measures: Exacerbation or relapse of psychotic symptoms;   Cognitive functioning based on Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery;   Role Functioning;   Cognitive performance on test battery (MCCB);   Insight (Awareness of Mental Disorder);   Retention in treatment;   Social functioning;   Emotional reactivity on psychophysiological measures
6 Recruiting Risperidone and Desipramine in Alcohol Use and Schizophrenia
Conditions: Schizophrenia;   Alcoholism;   Dual Diagnosis
Interventions: Drug: Risperidone + Desipramine;   Drug: Risperidone + Placebo
Outcome Measure: Timeline Followback
7 Recruiting Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders
Conditions: Attention Deficit/Hyperactivity Disorder;   Oppositional Defiant Disorder;   Conduct Disorder
Interventions: Drug: Methylphenidate;   Drug: Risperidone
Outcome Measures: Change from baseline of aggressive behaviors.;   Clinical Global Impression - Improvement scale (CGI-I) questionnaire;   ADHD-RS questionnaire;   Children's Depression Rating Scale (CDRS) questionnaire;   Young Mania Rating Scale (YMRS) questionnaire;   Children Sleep Habits Questionnaire (CSHQ);   Clinical Global Impression - Severity (CGI-S) questionnaire
8 Unknown  Repetitive Transcranial Magnetic Stimulation for First-episode Schizophrenia Patients
Condition: Schizophrenia
Interventions: Other: active Risperidone and active rTMS;   Other: active rTMS and sham Risperidone;   Other: sham rTMS and active Risperidone
Outcome Measures: PANSS;   Total AHRS score;   HAMD Score;   CGI;   fMRI
9 Not yet recruiting Bioavailability of LY03004 and Risperdal® Consta®
Conditions: Schizophrenia;   Schizoaffective Disorder
Interventions: Drug: LY03004;   Drug: Risperdal® Consta®
Outcome Measures: Cmax, Tmax, for Relative bioavailability of LY03004 compared to Risperdal® Consta®;   Number of Participants with Adverse Events as a Measure of Safety and Tolerability;   The change of the PANSS score for the Preliminary efficacy of LY03004
10 Unknown  Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone
Condition: Schizophrenia
Interventions: Drug: Sertindole;   Drug: Risperidone
Outcome Measures: cognitive functioning;   Discontinuation due to all causes, symptomatology and adverse events.
11 Unknown  Risperidone Treatment In Children With Autism Spectrum Disorder And High Levels Of Repetitive Behavior
Condition: Autism
Intervention: Drug: Risperidone
Outcome Measure: Aberrant Behavior Checklist
12 Recruiting Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)
Condition: Autistic Disorder
Interventions: Drug: Aripiprazole;   Drug: Risperidone
Outcome Measure: To identify phenotypic and genetic traits that predict response to aripiprazole and risperidone in Autistic Disorder
13 Recruiting A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Paliperidone extended-release;   Drug: Risperidone immediate-release
Outcome Measures: Change in category fluency score of cognitive function scale (Cognitive Abilities Screening Instrument, Chinese version [CASI C-2.0]) from baseline to Week 24;   Change from baseline to Week 24 in score of Modified Wisconsin Card Sorting Test (MWCST) short version;   Change from baseline in score of Continuous Performance Test (CPT);   Change from baseline in score of Personal and Social Performance (PSP) scale;   Change from baseline in score of Positive and Negative Syndrome Scale (PANSS);   Change from baseline in score of Clinical Global Impression-severity (CGI-S) scale;   Change from baseline in score of Medication Satisfaction Questionnaire (MSQ)
14 Unknown  Risperidone and Zotepine in the Treatment of Delirium
Condition: Delirium
Intervention: Drug: Risperidone and Zolpidem for delirium
Outcome Measures: Delirium rating scale;   MMSE, CGI, side effect profile, HRV
15 Recruiting Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia
Condition: Schizophrenia
Intervention: Drug: Risperidone ISM
Outcome Measures: Peak Plasma Concentration (Cmax) for Active Moiety;   Trough Plasma Concentration (Cmin) for Active Moiety;   Area under the curve to the last quantified concentration (AUClast) and Area under the curve extrapolated to infinity (AUC∞) for Active Moiety;   Terminal rate constant (λz), Terminal half-life (t1/2) and Time to peak concentration (tmax) for Active Moiety;   Peak Plasma Concentration (Cmax) for Risperidone and 9OH-Risperidone Moieties;   Trough Plasma Concentration (Cmin) for Risperidone and 9OH-Risperidone Moieties;   Occurrence, nature, onset time, duration, intensity, action taken, outcome and relationship to study drug of AEs as a Measure of Safety;   Area under the curve to the last quantified concentration (AUClast) and Area under the curve extrapolated to infinity (AUC∞) for Risperidone and 9OH-Risperidone Moieties;   Terminal rate constant (λz), Terminal half-life (t1/2) and Time to peak concentration (tmax) for Risperidone and 9OH-Risperidone Moieties;   Area Under the Concentration-time Curve​ for To perform a descriptive comparison of the PK data between the gluteal and the deltoid muscle administration of the injectable ISM formulation
16 Recruiting Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium
Conditions: Delirium;   Agitation
Interventions: Drug: Risperidone;   Drug: Trazodone;   Drug: Placebo
Outcome Measures: The number of days patients are without delirium during the study period (delirium-free days);   Daily prevalence of delirium as indicated by a positive Confusion Assessment Method in the ICU (CAM-ICU);   Resolution of delirium as indicated by a negative Confusion Assessment Method in the ICU (CAM-ICU) for more than 24 hours;   The number of patients who require rescue medications, the type of rescue medications utilized, and the amount of rescue medications per day;   The number of patients who receive sedative agents, amount of midazolam equivalents per day, and the number of days in which patients receive a sedative agent;   The number of patients who receive pain medications, amount of fentanyl equivalents per day, and the number of days in which patients receive a pain medication;   The number of hours spent agitated (RASS score between +4 and +2) as a percent of the time that the study drug was administered;   The number of hours spent excessively sedated or in a coma state (RASS score between -4 to -5) as a percent of the time that the study drug was administered;   The duration of mechanical ventilation from initial intubation to extubation as long as the patient remained extubated for more than 48 hours.;   The number of days that the patients were alive and breathing without assistance during the study period (ventilator-free days);   The number of episodes and number of patients who experience clinically significant QTc prolongation (≥ 500 msec or an increase of more than 60 msec from baseline);   The number of episodes and number of patients who experience clinically significant extrapyramidal effects (as evidenced by a positive Simpson-Angus Scale Score);   All-cause mortality and 28-day mortality
17 Unknown  Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia
Conditions: Smoking Cessation;   Schizophrenia
Interventions: Drug: Tropisetron;   Drug: Placebo;   Drug: Risperidone
Outcome Measures: Cognitive deficits as assessed by tests measuring the MATRICS cognition domains;   Negative schizophrenic symptoms;   Reduction in side effects of risperidone;   Abnormality in P50 inhibition;   Nicotine use among all participants who smoke
18 Recruiting A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone
Condition: Schizophrenia
Interventions: Drug: RO5545965;   Other: Placebo;   Drug: risperidone
Outcome Measures: Incidence of adverse events;   Health of the patients, assessed through a complete medical examination including physical examination, electrocardiogram (ECG) and vital signs.;   Pharmacokinetics: Plasma area under the concentration-time curve (AUC) of RO5545965;   Pharmacokinetics: Plasma area under the concentration-time curve (AUC) of risperidone
19 Not yet recruiting Brain Myelination Effects of Paliperidone Palmitate Versus Oral Risperidone in First Episode Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Paliperidone Palmitate;   Drug: Risperidone
Outcome Measures: Intracortical myelin;   Cognition;   Biomarker
20 Unknown  Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder
Interventions: Drug: Risperdal Consta (drug);   Behavioral: Social Skills Training
Outcome Measures: Scores on an analogue measure of responsiveness to skills training.;   Scores on a measure of skills acquisition and performance pre-post a 3-month skills training group.;   Interview measures of social functioning.;   Neurocognitive functioning.;   Symptomatology.

These studies may lead to new treatments and are adding insight into Risperdal etiology and treatment.

A major focus of Risperdal research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Risperdal